SEC Form 4 · accession 0001329154-26-000003
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Rosenblum
Officer — Chief Financial Officer
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 5:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 31, 2026 | A | 9,682 | $0.00 | A | 11,363 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
- F2Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.